Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Mini Review Volume 4 Issue 2

Mesoporous Silica Nanoparticles And its Current Approach’s to Curtail Multi Drug Resistance in Malignant Tumour: A Mini Review

Sankha Bhattacharya*

Associate Professor, Department of Pharmaceutics, ISF College of Pharmacy, Punjab, India

*Corresponding Author: Sankha Bhattacharya, Associate Professor, Department of Pharmaceutics, ISF College of Pharmacy, Punjab, India.

Received: December 26, 2019; Published: January 07, 2020



  Nanotechnology is playing a palpable role to circumvent any forms of cancer. But multi drug resistance (MDR) in malignant tumour tissues is a serious concern for nanotechnology to address. Among all the nanocarrier, mesoporous silica nanoparticles (MSNs) could be a promising candidate to tackle this challenge. This review is mainly focused on MSMs based approaches which are showing exciting results while treating MDR. The review is also highlighting the upcoming challenges associated with MSMs formulations while tackling MDR using MSMs approach.

Keywords: Cancer Treatment; Multidrug Resistance; Co-Delivery; Combination Therapy; Dual Targeting; Mesoporous Silica Nanoparticles



  1. Baselga J. “Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials”. Oncology 61 (2001): 14-21.
  2. Paul SM., et al. “How to improve R&D productivity: the pharmaceutical industry's grand challenge”. Nature Reviews Drug Discovery 9.3 (2010): 203.
  3. Randle HW. “Basal Cell Carcinoma Identification and Treatment of the High‐Risk Patient”. Dermatologic Surgery 22.3 (1996): 255-261.
  4. Andrews GP., et al. “Mucoadhesive polymeric platforms for controlled drug delivery”. European Journal of Pharmaceutics and Biopharmaceutics 71.3 (2009): 505-518.
  5. Ernsting MJ., et al. “Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles”. Journal of Controlled Release 172.3 (2013): 782-794.
  6. Watermann A and J Brieger. “Mesoporous silica nanoparticles as drug delivery vehicles in cancer”. Nanomaterials 7.7 (2017): 189.
  7. Emeje MO., et al. “Nanotechnology in drug delivery”. Recent advances in novel drug carrier systems (2012): 69-106.
  8. Sun X. “Mesoporous silica nanoparticles for applications in drug delivery and catalysis” (2012).
  9. McCarthy CA., et al. “Mesoporous silica formulation strategies for drug dissolution enhancement: a review”. Expert Opinion on Drug Delivery 13.1 (2016): 93-108.
  10. Lee BY., et al. “Redox‐triggered release of moxifloxacin from mesoporous silica nanoparticles functionalized with disulfide snap‐tops enhances efficacy against pneumonic tularemia in mice”. Small 12.27 (2016): 3690-3702.
  11. Avnir D., et al. “Enzymes and other proteins entrapped in sol-gel materials”. Chemistry of Materials 6 (1994): 1605-1614.
  12. Huo Q., et al. “Room temperature growth of mesoporous silica fibers: A new high‐surface‐area optical waveguide”. Advanced Materials 9 (1997): 974-978.
  13. Slowing II., et al. “Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers”. Advanced Drug Delivery Reviews 60.11 (2008): 1278-1288.
  14. Peik-See T., et al. “Simultaneous electrochemical detection of dopamine and ascorbic acid using an iron oxide/reduced graphene oxide modified glassy carbon electrode”. Sensors 14.8 (2014): 15227-15243.
  15. Chen Y., et al. “Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy”. ACS nano 4.1 (2009): 529-539.
  16. Hu J., et al. “Selective oxidation of styrene to benzaldehyde catalyzed by Schiff base-modified ordered mesoporous silica materials impregnated with the transition metal-monosubstituted Keggin-type polyoxometalates”. Applied Catalysis A: General 364 (2009): 211-220.
  17. Lee J.E., et al. “Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications”. Accounts of Chemical Research 44.10 (2011): 893-902.
  18. Argyo, C., et al. “Multifunctional mesoporous silica nanoparticles as a universal platform for drug delivery”. Chemistry of Materials 26 (2013): 435-451.
  19. Mehmood A., et al. “Mesoporous silica nanoparticles: a review”. Developing Drugs Journals 6 (2017.).
  20. Dean M., et al. “Tumour stem cells and drug resistance”. Nature Reviews Cancer 5.4 (2005): 275.
  21. Ling V. “Multidrug resistance: molecular mechanisms and clinical relevance”. Cancer Chemotherapy and Pharmacology 40.1 (1997): S3-S8.
  22. Kartal-Yandim M., et al. “Molecular mechanisms of drug resistance and its reversal in cancer”. Critical Reviews in Biotechnology 36.4 (2016): 716-726.
  23. Ma P and RJ Mumper. “Anthracycline nano-delivery systems to overcome multiple drug resistance: a comprehensive review”. Nano today 8 (2013): 313-331.
  24. Bailly C. “Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy”. Chemical Reviews 112.7 (2012): 3611-3640.
  25. Glisovic, T., et al. “RNA‐binding proteins and post‐transcriptional gene regulation”. FEBS letters 582.14 (2008): 1977-1986.
  26. Borišev I., et al. “Nanoformulations of doxorubicin: how far have we come and where do we go from here?” Nanotechnology 29.8 (2018): 332002.
  27. Chen AM., et al. “Co‐delivery of doxorubicin and Bcl‐2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug‐resistant cancer cells”. Small 5.23 (2009): 2673-2677.
  28. Nooter K and H Herweijer. “Multidrug resistance (mdr) genes in human cancer”. British Journal of Cancer 63.5 (1991): 663.
  29. Nepali K., et al. “Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids”. European Journal of Medicinal Chemistry 77 (2014): 422-487.
  30. Fulda S., et al. “Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo”. Nature Medicine 8.8 (2002): 808.
  31. Tacar O., et al. “Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems”. Journal of pharmacy and pharmacology 65.2 (2013): 157-170.
  32. Hasan T., et al. “Photodynamic therapy of cancer”. Cancer medicine 7 (2003): 537-48.
  33. Karuppanapandian T., et al. “Reactive oxygen species in plants: their generation, signal transduction, and scavenging mechanisms”. Australian Journal of Crop Science 5.6 (2011): 709.
  34. Du X., et al. “Mesoporous silica nanoparticles with organo-bridged silsesquioxane framework as innovative platforms for bioimaging and therapeutic agent delivery”. Biomaterials 91 (2016): 90-127.
  35. Kozissnik B., et al. “Magnetic fluid hyperthermia: advances, challenges, and opportunity”. International Journal of Hyperthermia 29.8 (2013): 706-714.
  36. Shi S., et al. “Biomedical applications of functionalized hollow mesoporous silica nanoparticles: focusing on molecular imaging”. Nanomedicine 8.12 (2013): 2027-2039.
  37. Tang F., et al. “Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery”. Advanced Materials 24.12 (2012): 1504-1534.
  38. Macchiarini P., et al. “Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma”. Cancer 68 (1991): 706-713.
  39. Bilasy SE., et al. “Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis”. Pharmacological Reports 67.1 (2015): 102-114.
  40. Kwatra D., et al. “Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer”. Translational Cancer Research 2 (2013): 330-342.
  41. Carcaboso AM., et al. “Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas”. Cancer Research 70.11 (2010): 4499-4508.


Citation: Sankha Bhattacharya. “Mesoporous Silica Nanoparticles And its Current Approach’s to Curtail Multi Drug Resistance in Malignant Tumour: A Mini Review". Acta Scientific Pharmaceutical Sciences 4.2 (2020): 07-11.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

Contact US